Evaluation of the safety and efficacy of onartuzumab combined with mFOLFOX6 in patients with HER2-negative gastric cancer showed that adding onartuzumab to mFOLFOX6 failed to improve efficacy of c-Met immunohistochemically positive population or even the whole population (Shah et al., 2016). The gene discussed is ERBB2; the disease is gastric cancer.